JP6987501B2 - 医薬製剤用ｐｉ３ｋデルタ選択的抑制剤の改良形態 - Google Patents

医薬製剤用ｐｉ３ｋデルタ選択的抑制剤の改良形態 Download PDF

Info

Publication number
JP6987501B2
JP6987501B2 JP2016569636A JP2016569636A JP6987501B2 JP 6987501 B2 JP6987501 B2 JP 6987501B2 JP 2016569636 A JP2016569636 A JP 2016569636A JP 2016569636 A JP2016569636 A JP 2016569636A JP 6987501 B2 JP6987501 B2 JP 6987501B2
Authority
JP
Japan
Prior art keywords
disease
cancer
tgr
ptsa salt
crystal according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016569636A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017516785A5 (enExample
JP2017516785A (ja
Inventor
スワループ・クマール・ヴェンカタ・サティア・ヴァッカランカ
Original Assignee
ライゼン・ファーマシューティカルズ・エスアー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライゼン・ファーマシューティカルズ・エスアー filed Critical ライゼン・ファーマシューティカルズ・エスアー
Publication of JP2017516785A publication Critical patent/JP2017516785A/ja
Publication of JP2017516785A5 publication Critical patent/JP2017516785A5/ja
Application granted granted Critical
Publication of JP6987501B2 publication Critical patent/JP6987501B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016569636A 2014-05-27 2015-05-26 医薬製剤用ｐｉ３ｋデルタ選択的抑制剤の改良形態 Expired - Fee Related JP6987501B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN2597/CHE/2014 2014-05-27
IN2596/CHE/2014 2014-05-27
IN2596CH2014 2014-05-27
IN2597CH2014 2014-05-27
PCT/IB2015/053940 WO2015181728A1 (en) 2014-05-27 2015-05-26 Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020088147A Division JP2020122022A (ja) 2014-05-27 2020-05-20 医薬製剤用ｐｉ３ｋデルタ選択的抑制剤の改良形態

Publications (3)

Publication Number Publication Date
JP2017516785A JP2017516785A (ja) 2017-06-22
JP2017516785A5 JP2017516785A5 (enExample) 2017-08-03
JP6987501B2 true JP6987501B2 (ja) 2022-01-05

Family

ID=53499042

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016569636A Expired - Fee Related JP6987501B2 (ja) 2014-05-27 2015-05-26 医薬製剤用ｐｉ３ｋデルタ選択的抑制剤の改良形態
JP2020088147A Pending JP2020122022A (ja) 2014-05-27 2020-05-20 医薬製剤用ｐｉ３ｋデルタ選択的抑制剤の改良形態
JP2022062937A Pending JP2022082680A (ja) 2014-05-27 2022-04-05 医薬製剤用ｐｉ３ｋデルタ選択的抑制剤の改良形態

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020088147A Pending JP2020122022A (ja) 2014-05-27 2020-05-20 医薬製剤用ｐｉ３ｋデルタ選択的抑制剤の改良形態
JP2022062937A Pending JP2022082680A (ja) 2014-05-27 2022-04-05 医薬製剤用ｐｉ３ｋデルタ選択的抑制剤の改良形態

Country Status (22)

Country Link
US (4) US9969740B2 (enExample)
EP (2) EP3971188A1 (enExample)
JP (3) JP6987501B2 (enExample)
KR (1) KR20170007480A (enExample)
CN (2) CN106661030B (enExample)
AU (1) AU2015265542B2 (enExample)
BR (1) BR112016027674A2 (enExample)
CA (1) CA2949932C (enExample)
CY (1) CY1124316T1 (enExample)
DK (1) DK3149000T3 (enExample)
EA (1) EA032506B1 (enExample)
ES (1) ES2880999T3 (enExample)
HR (1) HRP20211151T1 (enExample)
HU (1) HUE054916T2 (enExample)
IL (1) IL249058B2 (enExample)
LT (1) LT3149000T (enExample)
PL (1) PL3149000T3 (enExample)
PT (1) PT3149000T (enExample)
RS (1) RS62136B1 (enExample)
SI (1) SI3149000T1 (enExample)
SM (1) SMT202100532T1 (enExample)
WO (1) WO2015181728A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022082680A (ja) * 2014-05-27 2022-06-02 ライゼン・ファーマシューティカルズ・エスアー 医薬製剤用ｐｉ３ｋデルタ選択的抑制剤の改良形態

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3024123A1 (en) 2016-05-27 2017-11-30 Tg Therapeutics, Inc. Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders
BR112019004185A2 (pt) 2016-09-09 2019-09-03 Lab Francais Du Fractionnement combinação de um anticorpo anti-cd20, inibidor de pi3-quinase-delta inibidor e anticorpo anti-pd-1 ou anti-pd-l1 para tratamento de cânceres hematológicos
CA3146785A1 (en) * 2019-07-15 2021-01-21 Johnson Matthey Public Limited Company Amorphous umbralisib monotosylate
US20220143026A1 (en) 2020-11-12 2022-05-12 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1278748B1 (en) 2000-04-25 2011-03-23 ICOS Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
BRPI0316779B1 (pt) 2002-12-16 2020-04-28 Genentech Inc anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
US20100202963A1 (en) 2008-11-13 2010-08-12 Gallatin W Michael Therapies for hematologic malignancies
CN102439012A (zh) 2009-03-24 2012-05-02 吉里德卡利斯托加公司 2-嘌呤基-3-甲苯基-喹唑啉酮衍生物的阻转异构体和使用方法
CA2759724A1 (en) 2009-04-20 2010-10-28 Calistoga Pharmaceuticals, Inc. Methods of treatment for solid tumors
JP6181173B2 (ja) * 2012-07-04 2017-08-16 ライゼン・ファーマシューティカルズ・エスアー 選択的ｐｉ３ｋデルタ阻害剤
PT3149000T (pt) * 2014-05-27 2021-07-27 Rhizen Pharmaceuticals S A Sal tosilato cristalino de um inibidor seletivo de pi3k delta para uso em formulações farmacêuticas

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022082680A (ja) * 2014-05-27 2022-06-02 ライゼン・ファーマシューティカルズ・エスアー 医薬製剤用ｐｉ３ｋデルタ選択的抑制剤の改良形態

Also Published As

Publication number Publication date
JP2022082680A (ja) 2022-06-02
IL249058B (en) 2022-11-01
SI3149000T1 (sl) 2021-09-30
PT3149000T (pt) 2021-07-27
HUE054916T2 (hu) 2021-10-28
US10414773B2 (en) 2019-09-17
IL249058A0 (en) 2017-01-31
DK3149000T3 (da) 2021-08-30
PL3149000T3 (pl) 2021-11-02
US20210269446A1 (en) 2021-09-02
EP3149000A1 (en) 2017-04-05
RS62136B1 (sr) 2021-08-31
AU2015265542B2 (en) 2019-05-09
US20170121336A1 (en) 2017-05-04
BR112016027674A2 (pt) 2017-08-15
AU2015265542A1 (en) 2016-12-08
EP3971188A1 (en) 2022-03-23
HRP20211151T1 (hr) 2021-10-15
LT3149000T (lt) 2021-09-10
US10947244B2 (en) 2021-03-16
US20190016725A1 (en) 2019-01-17
CA2949932C (en) 2021-08-10
JP2020122022A (ja) 2020-08-13
US9969740B2 (en) 2018-05-15
EA201692255A1 (ru) 2017-04-28
JP2017516785A (ja) 2017-06-22
CY1124316T1 (el) 2022-07-22
CA2949932A1 (en) 2015-12-03
CN106661030B (zh) 2020-06-30
EA032506B1 (ru) 2019-06-28
EP3149000B1 (en) 2021-06-30
KR20170007480A (ko) 2017-01-18
CN111635406A (zh) 2020-09-08
CN106661030A (zh) 2017-05-10
SMT202100532T1 (it) 2021-11-12
ES2880999T3 (es) 2021-11-26
WO2015181728A1 (en) 2015-12-03
IL249058B2 (en) 2023-03-01
US20190382411A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
JP6987501B2 (ja) 医薬製剤用ｐｉ３ｋデルタ選択的抑制剤の改良形態
JP6523490B2 (ja) ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法
AU2022216284A1 (en) Combination therapy for treating abnormal cell growth
JP2020526492A (ja) Ｇ１ｔ３８の形態及びその製造方法
TW202131930A (zh) 抗癌核荷爾蒙受體標靶化合物
WO2023035223A1 (zh) 药物组合物及其用途
CA3153456A1 (en) Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
CN114450278B (zh) 一个烟醇醚衍生物的马来酸盐及其晶型和应用
JP2022522395A (ja) 選択的エストロゲン受容体分解剤の新規な塩
HK1236026B (en) Crystalline tosylate salt of a pi3k delta selective inhibitor for use in pharmaceutical formulations
TW202108570A (zh) 抗癌核荷爾蒙受體標靶化合物
TW201924719A (zh) 抑制腫瘤移轉的方法
CN100494177C (zh) 具有抗肿瘤活性的双酰胺基杂环类衍生物及其制备方法和用途
EA042667B1 (ru) Улучшенные формы селективного ингибитора pi3k-дельта для применения в фармацевтических препаратах
HK40042000B (zh) 苯并氧氮杂䓬恶唑烷酮化合物及其使用方法
HK40110967A (zh) 药物组合物及其用途
HK40039385B (zh) 苯并氧氮杂䓬恶唑烷酮化合物及其使用方法
BR112019027967B1 (pt) Forma b cristalina isolada, composição farmacêutica, uso de um composto ou composição, e, processo para produzir forma b cristalina

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190701

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200520

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200520

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200527

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200601

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200807

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200817

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210208

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210329

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210412

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210629

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20211004

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20211101

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20211101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211201

R150 Certificate of patent or registration of utility model

Ref document number: 6987501

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees